

# Mohamed bouattour

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4272226/publications.pdf>

Version: 2024-02-01

57  
papers

3,391  
citations

331670

21  
h-index

182427

51  
g-index

59  
all docs

59  
docs citations

59  
times ranked

4675  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.	1.6	1,255
2	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1624-1636.	10.7	595
3	Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. <i>Hepatology</i> , 2018, 67, 1132-1149.	7.3	190
4	Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. <i>Hepatology</i> , 2018, 68, 103-112.	7.3	159
5	Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified) Tj ETQq1 1 0.784314 rgBT /Overlook Hepatocellular Carcinoma Treated With Sorafenib. <i>Oncologist</i> , 2014, 19, 394-402.	3.7	134
6	Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib. <i>Clinical Cancer Research</i> , 2011, 17, 4504-4512.	7.0	83
7	Systemic Treatment for Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 341-358.	7.7	82
8	Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?. <i>Journal of Hepatology</i> , 2018, 69, 548-550.	3.7	71
9	Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1106-1110.	1.6	65
10	ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 5859-5865.	7.0	64
11	Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011, 54, 1073-1078.	3.7	50
12	Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. <i>Histopathology</i> , 2021, 79, 36-46.	2.9	49
13	Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. <i>Targeted Oncology</i> , 2012, 7, 127-133.	3.6	45
14	Novel molecular therapies in hepatocellular carcinoma. <i>Liver International</i> , 2011, 31, 151-160.	3.9	38
15	Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma. <i>ESMO Open</i> , 2017, 2, e000238.	4.5	37
16	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 454-465.	8.1	36
17	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	4.9	36
18	Sunitinib in Hepatocellular Carcinoma: Redefining Appropriate Dosing, Schedule, and Activity End Points. <i>Journal of Clinical Oncology</i> , 2009, 27, e248-e250.	1.6	33

#	ARTICLE	IF	CITATIONS
19	Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular and cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 2386-2396.	3.9	32
20	Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS. <i>JHEP Reports</i> , 2021, 3, 100380.	4.9	29
21	Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 6207-6216.	6.7	23
22	Prospective evaluation of the management of hepatocellular carcinoma in the elderly. <i>Digestive and Liver Disease</i> , 2011, 43, 1001-1005.	0.9	22
23	Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. <i>Investigational New Drugs</i> , 2014, 32, 1028-1035.	2.6	21
24	Management of immune-related adverse events resulting from immune checkpoint blockade. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 209-222.	2.4	20
25	Health-related quality of life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. <i>Cancer</i> , 2021, 127, 865-874.	4.1	20
26	Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101491.	1.5	18
27	Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. <i>Clinical Pharmacokinetics</i> , 2019, 58, 983-1014.	3.5	17
28	Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101590.	1.5	17
29	Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlo</i>	1.0	14
30	PARP inhibition in treatment of pancreatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 939-945.	2.4	14
31	Enhancing capsule in hepatocellular carcinoma: intra-individual comparison between CT and MRI with extracellular contrast agent. <i>Diagnostic and Interventional Imaging</i> , 2021, 102, 735-742.	3.2	13
32	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	3.9	11
33	Computed Tomography-Derived Liver Surface Nodularity and Sarcopenia as Prognostic Factors in Patients with Resectable Metabolic Syndrome-Related Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 405-416.	1.5	10
34	Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). <i>European Journal of Cancer</i> , 2021, 154, 46-56.	2.8	10
35	Intratumoral Gas in Hepatocellular Carcinoma following Transarterial Chemoembolization: Associated Factors and Clinical Impact. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1623-1631.	0.5	9
36	Biological response under treatment and prognostic value of protein induced by vitamin K absence or antagonist-II in a French cohort of patients with hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1364-1372.	1.6	8

#	ARTICLE	IF	CITATIONS
37	Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. <i>World Journal of Hepatology</i> , 2015, 7, 2245.	2.0	8
38	Long-term outcomes following resection of hepatocellular adenomas with small foci of malignant transformation or malignant adenomas. <i>JHEP Reports</i> , 2021, 3, 100326.	4.9	7
39	Performance of non-invasive biomarkers compared with invasive methods for risk prediction of posthepatectomy liver failure in hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2022, 109, 455-463.	0.3	7
40	Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. <i>World Journal of Hepatology</i> , 2015, 7, 910.	2.0	6
41	Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?. <i>Journal of Clinical Oncology</i> , 2015, 33, 2484-2485.	1.6	6
42	Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM. <i>Trials</i> , 2016, 17, 563.	1.6	4
43	Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. <i>Clinical Therapeutics</i> , 2021, 43, 1201-1212.	2.5	4
44	Response evaluation using RECIST and CHOI criteria in patients with well-differentiated pancreatic neuroendocrine tumors (pNET) treated with sunitinib or everolimus. <i>Pancreatology</i> , 2012, 12, 516-517.	1.1	3
45	Atypical Presentation of Hepatocellular Carcinoma Mimicking a Gastric Hepatoid Adenocarcinoma. <i>Medicine (United States)</i> , 2015, 94, e1101.	1.0	3
46	Nurse coordinator roles in the management of patients with hepatocellular carcinoma: A French national survey. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101650.	1.5	3
47	Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review. <i>European Journal of Clinical Pharmacology</i> , 2022, , 1.	1.9	3
48	Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101731.	1.5	2
49	Blinded independent central response assessment using RECIST, mRECIST, and CHOI criteria in patients treated with sorafenib for advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 172-172.	1.6	1
50	Abstract B175: TGF- $\beta$ 2-R1 kinase inhibitors LY2157299 and LY364947 decrease motility and invasion in hepatocarcinoma (HCC) cells developing resistance to VEGFR/PDGFR kinase inhibitors.. <i>Molecular Cancer Therapeutics</i> , 2011, 10, B175-B175.	4.1	1
51	Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?â€”review of the open label phase III trial CONKO 005. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 399-402.	1.5	0
52	Enjeux et spÃ©cificitÃ©s de lâ€™Ã©valuation radiologique des tumeurs neuroendocrines pancrÃ©atiques traitÃ©es par les thÃ©rapies ciblÃ©es. <i>CancÃ©ro Digest</i> , 2012, , .	0.0	0
53	Abstract C268: MET-inhibition using SU11274 and HER-inhibitions with lapatinib impair proliferation, motility and invasion in hepatocellular carcinoma (HCC) and exhibits an increased efficacy un sorafenib-tolerant model.. , 2013, , .		0
54	The Sorafenib for Hepatocellular Carcinoma (HCC) in Adjuvant Setting: The End of the Story was Already Written?. <i>Gastroenterology &amp; Hepatology (Bartlesville, Okla)</i> , 2014, 1, .	0.1	0

#	ARTICLE	IF	CITATIONS
55	Abstract 3484: Ex-vivo cultures of freshly explanted tumor specimens (TIPCANÂ®), a potent translational approach for screening novel targeted agents. , 2014, , .		0
56	Abstract 221: Ex vivo cultures of freshly explanted tumors: a potent translational approach for screening novel targeted agents. , 2015, , .		0
57	Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers, 2022, 14, 2634.	3.7	0